| Literature DB >> 25991919 |
Zahra Bahadoran1, Asghar Ghasemi2, Parvin Mirmiran3, Fereidoun Azizi4, Farzad Hadaegh5.
Abstract
BACKGROUND AND AIM: The ability of inorganic nitrate and nitrite to convert to nitric oxide (NO), and some of its properties e.g. regulation of glucose metabolism, vascular homeostasis, and insulin signaling pathway, have recently raised the hypothesis that inorganic nitrate and nitrite could be potential therapeutic agents in type 2 diabetes. In this review, we reviewed experimental and clinical studies investigating the effect of nitrate/nitrite administration on various aspects of type 2 diabetes.Entities:
Keywords: Inorganic nitrate and nitrite; Insulin resistance; Nitric oxide; Type 2 diabetes
Year: 2015 PMID: 25991919 PMCID: PMC4436104 DOI: 10.1186/s12986-015-0013-6
Source DB: PubMed Journal: Nutr Metab (Lond) ISSN: 1743-7075 Impact factor: 4.169
Fig. 1The impaired NO pathway in type 2 diabetes. Several mechanisms have been proposed for impaired NO pathway in diabetic condition 1) Chronic hyperglycemia, increased oxidative stress, NF-κB activation, and accumulation of AGEs 2) Increased plasma levels of ADMA, an endogenous competitive inhibitor of NO synthase 3) Decreased NOS activity and production of NO from L-arginine, increased arginase activity, decreased L-arginine bioavailability and NO synthesis via NOS 4) Impaired insulin secretion and insulin resistance. NO; Nitric oxide, NOS; Nitric oxide synthase, ADMA; Asymmetric dimethylarginine, NF-κB; Nuclear factor κB, AGEs; advanced glycation end products
Altered metabolism of nitrate/nitrite in type 2 diabetic patients
| Author | Study population | Findings |
|---|---|---|
| Francesconi, 2001 [ | Type 2 diabetic patients | Decreased urinary excretion of nitrate/nitrite after glycemic control; a positive correlation between fasting plasma glucose and urinary nitrate/nitrite |
| Kawakatso, 2002 [ | Type 2 diabetic patients with and without complications, compared with healthy controls | Lower nitrate/nitrite concentration in diabetic patients without complications; a higher nitrate/nitrite level in diabetic group with coronary artery disease |
| Apakkan, 2003 [ | Type 2 diabetic patients, compared with healthy controls | Higher serum and urine nitrate/nitrite in diabetic patients |
| Zahedi, 2008 [ | Subjects with type 2 diabetes and metabolic syndrome, compared with healthy controls | Higher serum nitrate/nitrite concentrations in subjects with type 2 diabetes and metabolic syndrome |
| Shiekh, 2011 [ | Type 2 diabetic patients, compared with healthy controls | Lower plasma levels of nitrate in diabetic patients |
The effects of nitrate and nitrite on glucose and insulin homeostasis
| Author | Animal | Treatment | Outcomes |
|---|---|---|---|
| Carlstrom, 2010 [ | e-NOS deficient mice | Addition of NaNO3 drinking water at a concentration of 85 mg/l for 8–10 weeks | ↓ Fasting blood glucose and glycosylated hemoglobin |
| ↓ Pro-insulin to insulin ratio | |||
| Improved glucose tolerance test | |||
| Nystrom, 2012 [ | Male wistar rats | Intraperitoneal injection of NaNO2 or NaNO3 | ↑ Plasma nitrite concentration |
| ↑ Pancreatic islet blood flow without any effect on total pancreas blood flow | |||
| ↑ Plasma insulin concentration without any effect on glycemia | |||
| ↑ Insulin secretion from isolated rat islet | |||
| Sodium nitrate had no insulinotropic effects at either glucose concentration | |||
| Ohtake, 2015 [ | KKAy diabetic mice | Administration of NO2− in drinking water at a dose of 50 and 150 mg/l for 10 weeks | ↓ Glucose level and improve glucose tolerance test at dose of 150 mg/l |
| Improved insulin resistance, measured by HOMA-IR at both doses | |||
| ↑ GLUT4 translocation in the cell membrane of skeletal muscle | |||
| Jiang, 2015 [ | Db/db diabetic mice | Administration of 50 mg/l NaNO2 for 4 weeks | ↓ Fasting glucose concentration |
| ↓ Insulin concentration, ↑ insulin sensitivity and insulin signaling | |||
| ↑ GLUT4 translocation in skeletal muscle and adipose tissue | |||
| Khalifi, 2015 [ | Streptozotocin-induced diabetic rats | Administration of NaNO3 in drinking water at a dose of 100 mg/l for 8 weeks | Restored serum nitrate/nitrite to normal values |
| Improved glucose tolerance |
NaNo3, Sodium nitrate; NaNo2, sodium nitrite
Fig. 2Proposed mechanisms of effects of nitrate/nitrite on glucose homeostasis and insulin signaling. Nitrate/nitrite increase insulin secretion by increasing pancreatic islet blood flow (1) and activation of guanylyl cyclase and cGMP pathway (2). Nitrate/nitrite induce NO production and improve insulin resistance and glucose uptake by increasing gene expression of GLUT4 (3). Nitrate/nitrite increase nitrosation and insulin-independent translocation of GLUT4 and increase glucose uptake by skeletal muscle and adipose tissue (4). Nitrate/nitrite also inhibits production of reactive oxygen species (ROS) in adipoceytes and dephosphorylation activity of protein-tyrosine phosphatase 1B and then facilitate phosphorylation of insulin receptor substrate and subsequently GLUT4 translocation and glucose uptake (5). ROS; Reactive oxygen species, IRS; Insulin receptor substrate, PI3K; Phosphatydal inositol 3 kinase, PKB; Protein kinase B, GLUT4; Glucose transporter 4, NO; Nitric oxide
Beneficial effects of nitrate/nitrite administration on type 2 diabetes complications
| Author | Animal | Treatment | Outcomes |
|---|---|---|---|
| Ohtake, 2007 [ | Streptozotocin-induced diabetic male rats | Administration of nitrite in drinking water for 4 weeks | ↓ Serum malondialdehyde concentrations |
| ↑ Nitrite levels in the kidney | |||
| Improvement in glomerular injury parameters including urinary protein and albumin excretion, histopathological glomerular hypertrophy, and mesangial matrix accumulation | |||
| Carlstrom, 2011 [ | Sprague–Dawley rats subjected to unilateral nephrectomy and chronic high-salt diet | Administration of nitrate at doses of 0.14 and 1.4 g NaNO3/kg diet for 10 weeks | ↓ Proteinuria |
| Improvement of histological renal injury, cardiac hypertrophy and fibrosis | |||
| Restored tissue levels of bioactive nitrogen oxides | |||
| ↓ Plasma malondialdehyde concentration | |||
| ↓Urinary F2-isoprostanes and 8-hydroxy-2-deoxyguanosine | |||
| Attenuates increased plasma and urinary levels of dimethylarginine (an endogenous NOS inhibitor) | |||
| ↑ Serum L-arginine levels |
NaNo3; Sodium nitrate, NOS; Nitric oxide synthase